NASDAQ:SYRSSyros Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.57 +0.06 (+0.63 %) (As of 05/29/2020 02:07 PM ET) Add Compare Share Today's Range$9.23Now: $9.57▼$9.6850-Day Range$6.97MA: $8.80▼$10.1852-Week Range$4.26Now: $9.57▼$11.93Volume23,984 shsAverage Volume360,464 shsMarket Capitalization$437.25 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingSyros Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.17, Syros Pharmaceuticals has a potential upside of 37.6% from its current price of $9.57.Amount of Analyst CoverageSyros Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSyros Pharmaceuticals has received 329 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSyros Pharmaceuticals has received 303 “underperform” votes. (Add your “underperform” vote.)Community SentimentSyros Pharmaceuticals has received 52.06% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote “Outperform” if you believe SYRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have sold 198.96% more of their company's stock than they have bought. Specifically, they have bought $88,600.00 in company stock and sold $264,878.00 in company stock.Percentage Held by InsidersOnly 14.80% of the stock of Syros Pharmaceuticals is held by insiders.Percentage Held by Institutions98.23% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($1.62) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is -5.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS Previous Symbol CUSIPN/A CIK1556263 Webwww.syros.com Phone617-744-1340Debt Debt-to-Equity Ratio0.58 Current Ratio6.35 Quick Ratio6.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.98 million Price / Sales220.84 Cash FlowN/A Price / Cash FlowN/A Book Value$1.68 per share Price / Book5.70Profitability EPS (Most Recent Fiscal Year)($1.88) Net Income$-75,440,000.00 Net Margins-1,950.42% Return on Equity-84.15% Return on Assets-50.21%Miscellaneous Employees76 Outstanding Shares45,690,000Market Cap$437.25 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:SYRS Rates by TradingView Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYRS shares have increased by 85.8% and is now trading at $9.57. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syros Pharmaceuticals. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Syros Pharmaceuticals. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.06. The business had revenue of $2.38 million for the quarter, compared to the consensus estimate of $1.72 million. Syros Pharmaceuticals had a negative net margin of 1,950.42% and a negative return on equity of 84.15%. View Syros Pharmaceuticals' earnings history. What price target have analysts set for SYRS? 6 equities research analysts have issued twelve-month price targets for Syros Pharmaceuticals' stock. Their forecasts range from $8.00 to $18.00. On average, they expect Syros Pharmaceuticals' stock price to reach $13.17 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View analysts' price targets for Syros Pharmaceuticals. Has Syros Pharmaceuticals been receiving favorable news coverage? News stories about SYRS stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a news impact score of 1.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days. View the latest news aboutSyros Pharmaceuticals. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,830,000 shares, an increase of 19.4% from the April 15th total of 2,370,000 shares. Based on an average trading volume of 248,100 shares, the days-to-cover ratio is presently 11.4 days. Approximately 8.8% of the company's stock are short sold. View Syros Pharmaceuticals' Current Options Chain. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include Zymeworks (ZYME), Heron Therapeutics (HRTX), Aurinia Pharmaceuticals (AUPH), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Arvinas (ARVN), Zogenix (ZGNX), Akebia Therapeutics (AKBA), Theravance Biopharma (TBPH), Y-mAbs Therapeutics (YMAB), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Passage Bio (ZNTL) and Akcea Therapeutics (AKCA). View all competitors. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Zynerba Pharmaceuticals (ZYNE), Abeona Therapeutics (ABEO) and Nektar Therapeutics (NKTR). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the following people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)Dr. David A. Roth, Chief Medical Officer (Age 56)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." Who are Syros Pharmaceuticals' major shareholders? Syros Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (10.78%), Nikko Asset Management Americas Inc. (11.35%), Sumitomo Mitsui Trust Holdings Inc. (11.35%), Arch Venture Corp (6.71%), BlackRock Inc. (6.16%) and JPMorgan Chase & Co. (1.93%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Mark J Alles, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View institutional ownership trends for Syros Pharmaceuticals. Which major investors are selling Syros Pharmaceuticals stock? SYRS stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, JPMorgan Chase & Co., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., BlackRock Inc., Morgan Stanley, and Squarepoint Ops LLC. Company insiders that have sold Syros Pharmaceuticals company stock in the last year include Richard A Young, and Venture Fund Vii LP Arch. View insider buying and selling activity for Syros Pharmaceuticals. Which major investors are buying Syros Pharmaceuticals stock? SYRS stock was acquired by a variety of institutional investors in the last quarter, including Portolan Capital Management LLC, Invesco Ltd., Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, AlpInvest Partners B.V., AQR Capital Management LLC, SG Americas Securities LLC, and Alliancebernstein L.P.. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, Mark J Alles, and Srinivas Akkaraju. View insider buying and selling activity for Syros Pharmaceuticals. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $9.57. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $437.25 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe. What is Syros Pharmaceuticals' official website? The official website for Syros Pharmaceuticals is www.syros.com. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
